miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling

Wu,Qingwei; Zhao,Yingying; Sun,Yiyuan; Yan,Xiaojun; Wang,Peihua

doi:10.3892/or.2018.6177

miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling

Authors:
- Qingwei Wu
- Yingying Zhao
- Yiyuan Sun
- Xiaojun Yan
- Peihua Wang
View Affiliations

Affiliations: Department of Ear, Nose and Throat, The Ninth Affliated Hospital of Shanghai Jiao Tong University, Shanghai 200011, P.R. China
Published online on: January 2, 2018 https://doi.org/10.3892/or.2018.6177
Pages: 1461-1468

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Upregulation of programmed death 1 ligand 1 (PD-L1) in cancer cells and its ligation to PD-1 on T cells facilitates cancer cell escape from immune surveillance. Therapies with PD-1 or PD-L1 antibodies have resulted in marked clinical responses in various cancer types. Hence, modulators that inhibit PD-L1 expression in cancer cells may serve as a novel strategy by which to enhance host immune responses. In the present study, we investigated the effects of miR-375 on PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells by qRT-PCR and western blot analyses. We confirmed that miR-375 inhibited IFN-γ-induced PD-L1 surface expression in HNSCC cells, and we observed that Janus kinase 2 (JAK2) is a bona fide target of miR-375 and further activated signal transducer and activator of transcription 1 (STAT1). Additionally, miR-375-mediated inhibition of PD-L1 expression was dependent on the JAK2/STAT1 pathway. Therefore, by attenuating PD-1/PD-L1 signaling, miR-375 may also serve as a modulator to increase the cell immune responses to HNSCC.

View Figures

View References

1	Khalil DN, Smith EL, Brentjens RJ and Wolchok JD: The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 13:3942016. View Article : Google Scholar : PubMed/NCBI
2	Sharma P, Wagner K, Wolchok JD and Allison JP: Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nat Rev Cancer. 11:805–812. 2011. View Article : Google Scholar : PubMed/NCBI
3	Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015. View Article : Google Scholar : PubMed/NCBI
4	Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, et al: Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 28:1605–1611. 2017. View Article : Google Scholar : PubMed/NCBI
5	Li X, Zheng L, Zhang F, Hu J, Chou J, Liu Y, Xing Y and Xi T: STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer. Oncotarget. 7:23197–23211. 2016.PubMed/NCBI
6	Miao L, Liu K, Xie M, Xing Y and Xi T: miR-375 inhibits Helicobacter pylori-induced gastric carcinogenesis by blocking JAK2-STAT3 signaling. Cancer Immunology Immunother. 63:699–711. 2014. View Article : Google Scholar
7	Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L and Choi IH: Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 580:755–762. 2006. View Article : Google Scholar : PubMed/NCBI
8	Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, Freeman GJ and Ritz J: Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 4:e10088242015. View Article : Google Scholar : PubMed/NCBI
9	Coombs MR, Harrison ME and Hoskin DW: Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells. Cancer Lett. 380:424–433. 2016. View Article : Google Scholar : PubMed/NCBI
10	Cui F, Wang S, Lao I, Zhou C, Kong H, Bayaxi N, Li J, Chen Q, Zhu T and Zhu H: miR-375 inhibits the invasion and metastasis of colorectal cancer via targeting SP1 and regulating EMT-associated genes. Oncol Rep. 36:487–93. 2016. View Article : Google Scholar : PubMed/NCBI
11	Yi J, Jin L, Chen J, Feng B, He Z, Chen L and Song H: MiR-375 suppresses invasion and metastasis by direct targeting of SHOX2 in esophageal squamous cell carcinoma. Acta Biochim Biophys Sin. 49:159–169. 2017.PubMed/NCBI
12	Ding L, Xu Y, Zhang W, Deng Y, Si M, Du Y, Yao H, Liu X, Ke Y, Si J and Zhou T: MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2. Cell Res. 20:784–793. 2010. View Article : Google Scholar : PubMed/NCBI
13	Sheng B, Zhao L, Zang X, Zhen J and Chen W: miR-375 ameliorates sepsis by downregulating miR-21 level via inhibiting JAK2-STAT3 signaling. Biomed Pharmacother. 86:254–261. 2017. View Article : Google Scholar : PubMed/NCBI
14	Harris T, Jimenez L, Kawachi N, Fan JB, Chen J, Belbin T, Ramnauth A, Loudig O, Keller CE, Smith R, et al: Low-level expression of miR-375 correlates with poor outcome and metastasis while altering the invasive properties of head and neck squamous cell carcinomas. Am J Pathol. 180:917–928. 2012. View Article : Google Scholar : PubMed/NCBI
15	Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Sakurai D, Fujimura L, Kawakami K, Chiyomaru T, Yoshino H, Enokida H, et al: Tumor suppressive microRNA-375 regulates oncogene AEG-1/MTDH in head and neck squamous cell carcinoma (HNSCC). J Hum Genet. 56:595–601. 2011. View Article : Google Scholar : PubMed/NCBI
16	Jimenez L, Sharma VP, Condeelis J, Harris T, Ow TJ, Prystowsky MB, Childs G and Segall JE: MicroRNA-375 suppresses extracellular matrix degradation and invadopodial activity in head and neck squamous cell carcinoma. Arch Pathol Lab Med. 139:1349–1361. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ock CY, Kim S, Keam B, Kim M, Kim TM, Kim JH, Jeon YK, Lee JS, Kwon SK, Hah JH, et al: PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma. Oncotarget. 7:15901–15914. 2016. View Article : Google Scholar : PubMed/NCBI
18	Zhu X, Wen Z, Xu LZ and Darnell JE Jr: Stat1 serine phosphorylation occurs independently of tyrosine phosphorylation and requires an activated Jak2 kinase. Mol Cell Biol. 17:6618–6623. 1997. View Article : Google Scholar : PubMed/NCBI
19	Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI
20	Mann JE, Hoesli R, Michmerhuizen NL, Devenport SN, Ludwig ML, Vandenberg TR, Matovina C, Jawad N, Mierzwa M, Shuman AG, et al: Surveilling the potential for precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC. J Cancer. 8:332–344. 2017. View Article : Google Scholar : PubMed/NCBI
21	Yang W, Chen PW, Li H, Alizadeh H and Niederkorn JY: PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci. 49:2518–2525. 2008. View Article : Google Scholar : PubMed/NCBI